TransMedics Group, Inc. (TMDX)
70.78
-5.74
(-7.50%)
USD |
NASDAQ |
Oct 16, 16:00
70.88
+0.10
(+0.14%)
After-Hours: 20:00
TransMedics Group Research and Development Expense (Annual) : 69.06M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 69.06M |
| December 31, 2024 | 55.97M |
| December 31, 2023 | 36.06M |
| December 31, 2022 | 26.81M |
| December 31, 2021 | 22.30M |
| Date | Value |
|---|---|
| December 31, 2020 | 18.55M |
| December 31, 2019 | 19.65M |
| December 31, 2018 | 13.66M |
| December 31, 2017 | 14.96M |
| December 31, 2016 | 15.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp. | 2.052B |
| Abbott Laboratories | 2.889B |
| Alphatec Holdings, Inc. | 76.27M |
| Baxter International, Inc. | 503.00M |
| Becton, Dickinson & Co. | 1.265B |